Hospital Acquired Pneumonia (HAP) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Hospital Acquired Pneumonia (HAP) – Pipeline Review, H2 2017’, provides an overview of the Hospital Acquired Pneumonia (HAP) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hospital Acquired Pneumonia (HAP), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hospital Acquired Pneumonia (HAP) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Hospital Acquired Pneumonia (HAP)

The report reviews pipeline therapeutics for Hospital Acquired Pneumonia (HAP) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Hospital Acquired Pneumonia (HAP) therapeutics and enlists all their major and minor projects

The report assesses Hospital Acquired Pneumonia (HAP) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Hospital Acquired Pneumonia (HAP)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Hospital Acquired Pneumonia (HAP)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Hospital Acquired Pneumonia (HAP) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Achaogen Inc

Adenium Biotech ApS

Aridis Pharmaceuticals LLC

AstraZeneca Plc

Bayer AG

Cardeas Pharma Corp

Destiny Pharma Ltd

Dong-A Socio Holdings Co Ltd

Lakewood-Amedex Inc

MedImmune LLC

Meiji Seika Pharma Co Ltd

Melinta Therapeutics Inc

Merck & Co Inc

Motif Bio Plc

Nabriva Therapeutics AG

Polyphor Ltd

Sealife PHARMA GMBH

Shionogi & Co Ltd

Tetraphase Pharmaceuticals Inc

The Medicines Company

Theravance Biopharma Inc

Wockhardt Ltd

Zavante Therapeutics Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Hospital Acquired Pneumonia (HAP) - Overview 7

Hospital Acquired Pneumonia (HAP) - Therapeutics Development 8

Pipeline Overview 8

Pipeline by Companies 9

Products under Development by Companies 12

Hospital Acquired Pneumonia (HAP) - Therapeutics Assessment 16

Assessment by Target 16

Assessment by Mechanism of Action 18

Assessment by Route of Administration 20

Assessment by Molecule Type 22

Hospital Acquired Pneumonia (HAP) - Companies Involved in Therapeutics Development 24

Achaogen Inc 24

Adenium Biotech ApS 24

Aridis Pharmaceuticals LLC 25

AstraZeneca Plc 25

Bayer AG 26

Cardeas Pharma Corp 26

Destiny Pharma Ltd 27

Dong-A Socio Holdings Co Ltd 27

Lakewood-Amedex Inc 28

MedImmune LLC 28

Meiji Seika Pharma Co Ltd 29

Melinta Therapeutics Inc 29

Merck & Co Inc 30

Motif Bio Plc 30

Nabriva Therapeutics AG 31

Polyphor Ltd 31

Sealife PHARMA GMBH 32

Shionogi & Co Ltd 32

Tetraphase Pharmaceuticals Inc 33

The Medicines Company 33

Theravance Biopharma Inc 34

Wockhardt Ltd 34

Zavante Therapeutics Inc 35

Hospital Acquired Pneumonia (HAP) - Drug Profiles 36

(amikacin sulfate + fosfomycin) - Drug Profile 36

(avibactam + ceftazidime) - Drug Profile 38

(avibactam sodium + aztreonam lysine) - Drug Profile 43

(cefepime + zidebactam) - Drug Profile 45

(ceftolozane sulfate + tazobactam sodium) - Drug Profile 46

(cilastatin sodium + imipenem + relebactam) - Drug Profile 51

(meropenem+ vaborbactam) - Drug Profile 53

AA-139 - Drug Profile 57

Aerucin - Drug Profile 58

alalevonadifloxacin - Drug Profile 60

amikacin sulfate - Drug Profile 61

arbekacin - Drug Profile 63

ASN-100 - Drug Profile 64

cefiderocol - Drug Profile 67

delafloxacin meglumine - Drug Profile 71

EBX-004 - Drug Profile 80

eravacycline - Drug Profile 81

exeporfinium chloride - Drug Profile 88

fosfomycin tromethamine - Drug Profile 90

iclaprim mesylate - Drug Profile 93

lefamulin acetate - Drug Profile 98

levonadifloxacin - Drug Profile 103

MEDI-3902 - Drug Profile 104

Mul-1867 - Drug Profile 105

murepavadin - Drug Profile 107

Nu-2 - Drug Profile 109

Nu-3 - Drug Profile 110

Panaecin - Drug Profile 112

panobacumab - Drug Profile 113

plazomicin sulfate - Drug Profile 115

POL-7001 - Drug Profile 123

Qn-2251 - Drug Profile 124

SLP-0905 - Drug Profile 125

sodium hypochlorite - Drug Profile 126

suvratoxumab - Drug Profile 127

tedizolid phosphate - Drug Profile 128

telavancin hydrochloride - Drug Profile 136

tosatoxumab - Drug Profile 141

Viritron VDX - Drug Profile 143

Hospital Acquired Pneumonia (HAP) - Dormant Projects 144

Hospital Acquired Pneumonia (HAP) - Discontinued Products 145

Hospital Acquired Pneumonia (HAP) - Product Development Milestones 146

Featured News & Press Releases 146

Appendix 157

Methodology 157

Coverage 157

Secondary Research 157

Primary Research 157

Expert Panel Validation 157

Contact Us 157

Disclaimer 158

List of Tables

List of Tables

Number of Products under Development for Hospital Acquired Pneumonia (HAP), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Hospital Acquired Pneumonia (HAP) – Pipeline by Achaogen Inc, H2 2017

Hospital Acquired Pneumonia (HAP) – Pipeline by Adenium Biotech ApS, H2 2017

Hospital Acquired Pneumonia (HAP) – Pipeline by Aridis Pharmaceuticals LLC, H2 2017

Hospital Acquired Pneumonia (HAP) – Pipeline by AstraZeneca Plc, H2 2017

Hospital Acquired Pneumonia (HAP) – Pipeline by Bayer AG, H2 2017

Hospital Acquired Pneumonia (HAP) – Pipeline by Cardeas Pharma Corp, H2 2017

Hospital Acquired Pneumonia (HAP) – Pipeline by Destiny Pharma Ltd, H2 2017

Hospital Acquired Pneumonia (HAP) – Pipeline by Dong-A Socio Holdings Co Ltd, H2 2017

Hospital Acquired Pneumonia (HAP) – Pipeline by Lakewood-Amedex Inc, H2 2017

Hospital Acquired Pneumonia (HAP) – Pipeline by MedImmune LLC, H2 2017

Hospital Acquired Pneumonia (HAP) – Pipeline by Meiji Seika Pharma Co Ltd, H2 2017

Hospital Acquired Pneumonia (HAP) – Pipeline by Melinta Therapeutics Inc, H2 2017

Hospital Acquired Pneumonia (HAP) – Pipeline by Merck & Co Inc, H2 2017

Hospital Acquired Pneumonia (HAP) – Pipeline by Motif Bio Plc, H2 2017

Hospital Acquired Pneumonia (HAP) – Pipeline by Nabriva Therapeutics AG, H2 2017

Hospital Acquired Pneumonia (HAP) – Pipeline by Polyphor Ltd, H2 2017

Hospital Acquired Pneumonia (HAP) – Pipeline by Sealife PHARMA GMBH, H2 2017

Hospital Acquired Pneumonia (HAP) – Pipeline by Shionogi & Co Ltd, H2 2017

Hospital Acquired Pneumonia (HAP) – Pipeline by Tetraphase Pharmaceuticals Inc, H2 2017

Hospital Acquired Pneumonia (HAP) – Pipeline by The Medicines Company, H2 2017

Hospital Acquired Pneumonia (HAP) – Pipeline by Theravance Biopharma Inc, H2 2017

Hospital Acquired Pneumonia (HAP) – Pipeline by Wockhardt Ltd, H2 2017

Hospital Acquired Pneumonia (HAP) – Pipeline by Zavante Therapeutics Inc, H2 2017

Hospital Acquired Pneumonia (HAP) – Dormant Projects, H2 2017

Hospital Acquired Pneumonia (HAP) – Discontinued Products, H2 2017

List of Figures

List of Figures

Number of Products under Development for Hospital Acquired Pneumonia (HAP), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports